OncoZenge

Bolag

OncoZenge

ONCOZFirst North StockholmHälsovårdBioteknik

OncoZenge är ett svenskt läkemedelsbolag som utvecklar behandlingar för smärtlindring hos patienter som lider av oral smärta orsakad av strålbehandling och kemoterapi mot cancer. Bolagets produktkandidat är efter genomförda fas 2-studier under vidare utveckling till grund för ansökan om regulatoriska marknadsgodkännanden och kommersialisering. OncoZenge har sitt huvudkontor i Bromma.

Senaste publicering

2 april 2026

I databasen

11 publicerade PM

Webbplats

Besök bolagets sida

Senaste nyheter och pressmeddelanden

Bolagets senaste flöde, utan extra fluff.

11 visade
10:5502 apr.
ONCOZ

OncoZenge Confirms Submission of Responses to EMA on the BupiZenge™ Phase III Trial (BZ003)

OncoZenge AB (publ), OncoZenge or "the Company", developing innovative treatments for oral pain management, today announced the complete submission of responses to European authorities' Requests for Information on the planned Phase III trial of BupiZengeTM, BZ003. The Company continues to expect a Clinical Trial Application (CTA) approval decision by late April or early May at the latest, consistent with the objective of first patient enrolment in Q2 2026.

07:1501 apr.
ONCOZ

OncoZenge Reports Positive Stability Results for BupiZenge™ as Key Enabler for the Upcoming Phase III Trial

OncoZenge AB (publ), a pharmaceutical company developing innovative treatments for oral pain management, today announced that the three-month stability study results for its BupiZengeTM lozenge are within specifications. The batch was successfully manufactured at Meribel Pharma Solutions in Solna, Sweden, in December 2025 following a technology transfer conducted in collaboration with Molteni Farmaceutici.

07:0026 feb.
ONCOZyear-end

OncoZenge AB Year-end Report January 1 – December 31, 2025

OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced its full year report for 2025, a year of significant progress culminating in the submission of the Phase III Clinical Trial Application for BupiZengeTM (BZ003) to the European Medicines Agency (EMA) in December. With trial sites selected across Norway, Sweden, Denmark and Germany, and GMP-manufactured clinical trial material ready, the Phase III program is on track to dose its first patient in Q2 2026, following regulatory approval.

08:4004 feb.
ONCOZ

OncoZenge AB Unveils Key Insights from UCLA Patient Engagement Study on Oral Mucositis Pain Management

OncoZenge AB (publ) (“OncoZenge” or “the Company”), a pharmaceutical company developing BupiZengeTM, an innovative non-opioid lozenge for localized relief from severe oral pain, today shared key findings from its patient engagement study conducted in collaboration with UCLA Health. The study, completed in December 2025, gathered perspectives from 43 patients undergoing or having completed radiation therapy for head and neck cancer, and a focus group discussion with four participants. These insights highlight unmet needs in managing oral mucositis pain and have directly informed optimizations to the design of OncoZenge's upcoming Phase III clinical trial for BupiZengeTM in Europe.

14:4030 jan.
ONCOZ

OncoZenge AB Reports Positive Initial Stability Results for the BupiZenge™ Technology Batch, Advancing Toward Clinical Trials

OncoZenge AB (publ), a pharmaceutical company developing innovative treatments for oral pain management, today announced that the one-month stability study results for its BupiZengeTM lozenge technology batch are within specifications. The batch was successfully manufactured at Meribel Pharma Solutions in Solna, Sweden, in December 2025 following a technology transfer conducted in collaboration with Molteni Farmaceutici.

18:1922 jan.
ONCOZ

OncoZenge enters into convertible loan agreement with Linc AB and gives an update on the payment of subscription proceeds

OncoZenge AB (publ) ("OncoZenge" or the “Company") has today entered into an agreement for a bridge financing solution of SEK 5 million, via a convertible note with Linc AB ("Linc") to be repaid upon payment of the third tranche in the directed share issue to Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the “Investor”), resolved by the Board of Directors of the Company and communicated on 19 December 2025 (the “Directed Share Issue”). Furthermore, the Company has received a written letter of commitment from the Investor that the Investor irrevocably will pay the subscription proceeds of approximately SEK 9.1 million in the Directed Share Issue on or before 21 February 2026. The Board of Directors has extended the time for payment in the Directed Share Issue until 21 February 2026 and has secured the Company’s liquidity for the period until that date, and following receipt of the subscription proceeds, until the middle of Q2 2026, in line with the CTA milestone in the existing financial plan.

16:3221 jan.
ONCOZ

OncoZenge announces uncertainty regarding payment of subscription proceeds and liquidity impact

OncoZenge AB (publ) (the “Company”) has just been informed that the strategic investor Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the “Investor”) will not be able to pay the subscription proceeds of approximately SEK 9.1 million by the end of the payment deadline in the directed share issue resolved by the Board of Directors of the Company and communicated on 19 December 2025.

07:5019 dec.
ONCOZ

OncoZenge resolves on a directed share issue to Sichuan Yangtian Bio-Pharmaceutical pursuant to existing investment agreement

The Board of Directors of OncoZenge AB (publ) (“OncoZenge” or the “Company”) has, based on the authorisation granted by the Annual General Meeting on 28 May 2025, resolved on a directed share issue of 1,400,894 shares to the strategic investor Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the “Investor”) at a subscription price of SEK 6.47 per share (the “Directed Share Issue”). The Directed Share Issue has been resolved upon after the Company has successfully submitted the complete phase III Clinical Trial Application (CTA) for BupizengeTM in Europe. All 1,400,894 shares have been formally subscribed for by the Investor and allotted by the Board of Directors, which means that the Company will receive approximately SEK 9.1 million before deduction of limited administrative transaction costs. The Directed Share Issue constitutes the third of four tranches under the SEK 30.2 million investment undertaking (the “Investment”), pursuant to the investment agreement entered into by the Company and the Investor on 27 January 2025 and previously communicated (the “Investment Agreement”).

OncoZenge aktie: nyheter, pressmeddelanden och analys | Tickr